Lithium was introduced into medicine more than one hundred years ago and into psychiatry 25 years ago. In spite of this long history, it is only within the last 5-10 years that the unique properties and particular advan tages of lithium as a drug have become recognized. Its usage is now sprea ding rapidly, and almost every month we hear of new uses being claimed for lithium. I want to emphasize, however, that at the present time only two uses of lithium are fully established: the therapeutic use in mania, and the prophylactic use in recurrent endogenous affective disorders. All other uses are based on evidence which is not yet fully conclusive even though in some instances it is quite strong. Systematic trials are required fox further substantiation. We must keep our minds open to new developments in the field, for there is presumably still much to be learned about this deceptively simple and yet so enigmatic drug, the lithium ion. This paper deals with indications for lithium treatment, the proven, the tentative, and the disproven. Another paper (Schou, 1975) describes the practical problems of lithium treatment.
for already existing depressive disorder (Mendels, 1973 (Mendels, , 1975 . Further ex perience may show whether there are some depressed patients who with benefit could be treated primarily with lithium.
There has been some uncertainty as to whether lithium administered concurrently with tricyclic antidepressant drugs might counteract their the rapeutic action in depression . Such a combi nation might be considered in cases where one wants to start prophylactic lithium treatment already during a depression in order to achieve effective prophylaxis against further recurrences as quickly as possible. The question was subjected to quantitative analysis in a multicenter study carried out in Scandinavia (Lingjaerde, 1973) , which showed that lithium did not diminish the antidepressant activity of tricyclic antidepressants; on the contrary, in some cases it seemed to potentiate it. Lithium prophylaxis can accordingly be started already during the depressive episode when the patient is in anti depressant treatment. Whether lithium in fact enhances the therapeutic action is a question which requires further study. Recurrent endogenous affective disorders of the polar and the monopolar type -The most controversial issue in the lithium field has been the pro phylactic action of lithium in recurrent endogenous affective disorders, that is, its ability to attenuate or prevent further manic and depressive episodes. When reports of such an action first appeared, the notion of prophylaxis was a relatively unknown one in psychiatry, and many psychiatrists found it difficult to believe in the reality of this phenomenon. The debate ge nerated by the first reports led to a useful clarification of methodological and conceptual issues and to the initiation of a number of further studies on lithium prophylaxis (reviews: Schou, 1973; Schou and Thomsen, 1975). The evidence for a prophylactic action of lithium in recurrent endogenous affective disorders is now very weighty and includes two-group double-blind studies as well as one-group non-blind studies. The latter were based on certain assumptions concerning the nature and the course of recurrent endo genous affective disorders; these assumptions have been validated.
There is hardly any reason to review all the studies, but it may be of interest to present briefly the outcome of the eight two-group double-blind studies on lithium prophylaxis. They differ somewhat as regards design, presentation of data, and statistical treatment of the results. In order to make their results comparable, we have derived new data from those pre sented originally by the authors and subjected them to independent statistical assessment (Schou and Thomsen, 1975). The design and special features of the trials are shown in Table 2 , where the studies are listed in chronological order. Their results appear from Table 3 , which shows the total number of patients in each trial; the number who completed the trials without suffering relapse, one or more, during the trial period; and the number who completed the trials without suffering relapse. The total number of patients is counted here as those who entered the trial minus those who dropped out of it for reasons other than relapse (intercurrent disease, pregnancy, side effects). Included in the number of patients who relapsed during the trial are those who dropped out because they relapsed as well as those who completed the trial in spite of one or more relapses.
It appears from the table that in each of the eight studies fewer patients suffered relapse among those given lithium than among those given placebo. In most instances the difference had a high degree of statistical significance. The studies where differences were not significant or where the significance reached only the 5% level were based on small patient groups or short trial periods. According to the two-group double-blind studies lithium exerts a prophylactic action against further recurrences of endogenous affective disorder that is clearly superior to that of placebo. Schou (1975) . It is to be hoped that further studies will be carried out, preferably with larger patient groups, longer observation periods, and attention paid also to the patient's mental condition during the intervals between episodes. If monitoring of plasma levels of tricyclic antidepressants turns out to be a guideline for drug adjustment, this feature should preferably also be included in future studies.
During recent years the assertion has occasionally been made that li thium exerts prophylactic action in bipolar cases

Recurrent schizo-affective
disorder -According to the first systematic study on lithium prophylaxis (Baastrup and Schou, 1967) lithium exerts a significant but less pronounced prophylactic action in patients with aty pical features than in those with typical bipolar or monopolar recurrent affective disorder. These studies have later been extended. Table 4 Li thium appeared to modify the patient's drinking habits significantly, whereas placebo had no effect. The patients given lithium had much fewer disabling drinking episodes than they had had before lithium and also than the patients given placebo. It is to be hoped that this study will be supplemented by others in which the clinical characteristics of the patients who respond to lithium are described in more detail.
Revusky (1973) has suggested using lithium as a sickness producing agent in aversion treatment of alcoholism. It would seem, however, that other procedures are preferable.
Opiate addiction -According to a single tentative report (Scher, 1972) , lithium administration to young heroine addicts led to partial or complete blocking of the euphoric response, relief of withdrawal symptoms, and reduction of the "heroine hunger". The report has not yet been substantiated by further studies. We ourselves tried to give lithium to young morphine addicts, but found them so unreliable as regards drug intake that a meaningful study could not be completed. A study carried out in U.S.A. was clearly negative (Bunney, 1974, personal communication) . 
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